Antibe Therapeutics Inc.
ATE
Clasificación en acciones
#31899
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Precio por acción
$0.21483059
Última sincronización: 2024-05-07
Capitalización bursátil
$11.13M
Cambio (1 día)
0.34%
Cambio (1 año)
-0.36%
País
CA
Comercio Antibe Therapeutics Inc. (ATE)
Categoría
Healthcare
Historial de rendimiento por dividendo de Antibe Therapeutics Inc. (ATE)
Rendimiento por dividendo (TTM) de Antibe Therapeutics Inc. (símbolo bursátil: ATE) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Antibe Therapeutics Inc. (ATE) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
| Año | Rendimiento por dividendo | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Rendimientos por dividendo (TTM) de empresas similares o competidoras
| Empresa | Rendimiento por dividendo | País |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
